{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:51:58Z","timestamp":1791373918597,"version":"4.3.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00120-026-02887-4","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:08:37Z","timestamp":1783436917000},"page":"1031-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00dcbertherapie des lokalisierten Prostatakarzinoms im Alter\u00a0\u2013 brauchen wir eine neue Definition klinischer Signifikanz?","Overtreatment of localized prostate cancer in older men\u2014do we need a\u00a0new definition of clinical significance?"],"prefix":"10.1007","volume":"65","author":[{"given":"Martin","family":"Umbehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Manseck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fr\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Piotrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schl\u00f6gl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"14","key":"2887_CR1","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMc2406108","volume":"391","author":"L Holmberg","year":"2024","unstructured":"Holmberg\u00a0L, Garmo\u00a0H, Andersson\u00a0SO, Andr\u00e9n\u00a0O, Johansson\u00a0E, Taari\u00a0K, H\u00e4ggman\u00a0M, Nordling\u00a0S, Busch\u00a0C, Adami\u00a0HO, Johansson\u00a0JE, Bill-Axelson\u00a0A (2024) Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. N Engl J Med 391(14):1362\u20131364","journal-title":"N Engl J Med"},{"issue":"10","key":"2887_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/sj.bjc.6603105","volume":"94","author":"C Parker","year":"2006","unstructured":"Parker\u00a0C, Muston\u00a0D, Melia\u00a0J, Moss\u00a0S, Dearnaley\u00a0D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10):1361\u20131368","journal-title":"Br J Cancer"},{"issue":"10","key":"2887_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","volume":"29","author":"PC Albertsen","year":"2011","unstructured":"Albertsen\u00a0PC, Moore\u00a0DF, Shih\u00a0W, Lin\u00a0Y, Li\u00a0H, Lu-Yao\u00a0GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J\u00a0Clin Oncol 29(10):1335\u20131341","journal-title":"J Clin Oncol"},{"key":"2887_CR4","doi-asserted-by":"crossref","unstructured":"Ventimiglia E, Gedeborg R, Styrke J, Robinson D, Stattin P, Garmo H. Natural History of Nonmetastatic Prostate Cancer Managed With Watchful Waiting. JAMA Netw Open. 2024 Jun 3;7(6)","DOI":"10.1001\/jamanetworkopen.2024.14599"},{"issue":"3","key":"2887_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/jnci\/djae200","volume":"117","author":"MR Cooperberg","year":"2025","unstructured":"Cooperberg\u00a0MR, Braun\u00a0AE, Berlin\u00a0A, Kibel\u00a0AS, Eggener\u00a0SE, CANCER-GG1 Writing Group (2025) When is prostate cancer really cancer? J\u00a0Natl Cancer Inst 117(3):402\u2013440","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2887_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00345-017-2038-0","volume":"35","author":"MR Cooperberg","year":"2017","unstructured":"Cooperberg\u00a0MR, Chan\u00a0JM (2017) Epidemiology of prostate cancer. World J Urol 35(6):849\u2013849","journal-title":"World J Urol"},{"key":"2887_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1100\/tsw.2011.79","volume":"11","author":"E Scott","year":"2011","unstructured":"Scott\u00a0E (2011) Prostate cancer. ScientificWorldJournal 11:749\u2013750","journal-title":"ScientificWorldJournal"},{"issue":"3","key":"2887_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer\u00a0EJ, Laversanne\u00a0M, Sung\u00a0H, Soerjomataram\u00a0I, Briganti\u00a0A, Dahut\u00a0W, Bray\u00a0F, Jemal\u00a0A (2025) Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol Oncol 87(3):302\u2013313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013","journal-title":"Eur Urol"},{"issue":"1","key":"2887_CR9","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Fuchs\u00a0HE, Jemal\u00a0A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"key":"2887_CR10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico\u00a0AV et\u00a0al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969\u2013974","journal-title":"JAMA"},{"key":"2887_CR11","unstructured":"https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/bevoelkerung\/geburten-todesfaelle\/lebenserwartung.html"},{"issue":"1","key":"2887_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1464-410X.2008.07614.x","volume":"102","author":"J Walz","year":"2008","unstructured":"Walz\u00a0J, Suardi\u00a0N, Shariat\u00a0SF, Jeldres\u00a0C, Perrotte\u00a0P, Graefen\u00a0M, Widmer\u00a0H, Arjane\u00a0P, Valiquette\u00a0L, Hutterer\u00a0G, Saad\u00a0F, Karakiewicz\u00a0PI (2008) Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int 102(1):33\u201338","journal-title":"BJU Int"},{"key":"2887_CR13","unstructured":"https:\/\/prostate.predict.cam\/tool"},{"key":"2887_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2147\/CMAR.S361495","volume":"14","author":"S Zhou","year":"2022","unstructured":"Zhou\u00a0S, Zhang\u00a0XH, Zhang\u00a0Y, Gong\u00a0G, Yang\u00a0X, Wan\u00a0WH (2022) The Age-Adjusted Charlson Comorbidity Index Predicts Prognosis in Elderly Cancer Patients. Cancer Manag Res 14:1683\u20131691","journal-title":"Cancer Manag Res"},{"key":"2887_CR15","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney\u00a0FI, Barthel\u00a0DW (1965) Functional Evaluation: The Barthel\u00a0Index. Md State Med J 14:61\u201365","journal-title":"Md State Med J"},{"issue":"1","key":"2887_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12877-020-01801-7","volume":"20","author":"S Church","year":"2020","unstructured":"Church\u00a0S, Rogers\u00a0E, Rockwood\u00a0K, Theou\u00a0O (2020) A scoping review of the Clinical Frailty Scale. BMC Geriatr 20(1):393\u2013393","journal-title":"BMC Geriatr"},{"key":"2887_CR17","volume":"34","author":"P M","year":"2020","unstructured":"M\u00a0P, A\u00a0A (2020) Assessment tools to evaluate Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) in older adults: A systematic review. Med J Islam Repub Iran 34:33","journal-title":"Med J Islam Repub Iran"},{"issue":"1","key":"2887_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/a-0875-0648","volume":"51","author":"Y Rassam","year":"2020","unstructured":"Rassam\u00a0Y, Schindler\u00a0A, Willschrei\u00a0P, Horstmann\u00a0M (2020) The G8 questionnaire as a\u00a0geriatric screening tool in urooncology. Aktuelle Urol 51(1):36\u201341","journal-title":"Aktuelle Urol"},{"issue":"4","key":"2887_CR19","first-page":"513","volume":"73","author":"H Chen","year":"2018","unstructured":"Chen\u00a0H, Rejeski\u00a0J, Gill\u00a0T, Guralnik\u00a0J, King\u00a0A et\u00a0al (2018) A Comparison of Self-report Indices of Major Mobility Disability to Failure on the 400\u2011m Walk Test: The LIFE Study Purchased. The Journals of Gerontology: Series A 73(4):513\u2013518","journal-title":"The Journals of Gerontology: Series A"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02887-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02887-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02887-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:09:52Z","timestamp":1791371392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02887-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2887"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02887-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Umbehr: Indirekte Interessen \u2013\u00a0Mitgliedschaften: Schweizerische Gesellschaft f\u00fcr Urologie SGU, Deutsche Gesellschaft f\u00fcr Urologie DGU. A.\u00a0Manseck: Berater- bzw. Gutachtert\u00e4tigkeiten: Gerichtsgutachter, Gutachter Landes\u00e4rztekammer;\n                      Mitarbeit in einem wissenschaftlichen Beirat (advisory board):\n                      F\u00f6rderverein zur Unterst\u00fctzung Krebskranker in der Region Ingolstadt e.\u202fV.; Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Urologie OnLine Veranstalter: DGU, UroWorxx, Veranstalter: Christine Gerner, Boston Scientific Medizintechnik GmbH; Autoren-\/oder Coautorenschaft:\n                      \n                      ; Indirekte Interessen\u00a0\u2013 Mitgliedschaften: Generalsekret\u00e4r der bayerischen Urologenvereinigung, Schriftf\u00fchrer im Arbeitskreis Geriatrische Urologie der Deutschen Gesellschaft f\u00fcr Urologie, Schriftf\u00fchrer und Schatzmeister im Arbeitskreis Laparoskopie und roboterassistierte Chirurgie der Deutschen Gesellschaft f\u00fcr Urologie, Fachexperte Fa. OnkoZert, Mitglied im Ausschuss Zertifikatserteilung der Fa. OnkoZert, Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Kommission Prostatakrebszentren\/Peniskarzinom (PZ), Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Modul Harnblasenkarzinomzentren (MB), Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Modul Nierenzellkarzinomzentren (MN). J.\u00a0Stein: Berater- bzw. Gutachtert\u00e4tigkeiten: Gutachter f\u00fcr Schlichtungsstellen \u00c4KN und \u00c4KHH, Fa. Bayer, AAA\/Novartis; Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Fa. Medac, Fa. Lilly; Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Firmen: Astellas, Boston Scientific, Dr. Pfleger, Medtronic, Medac, Sanofi, Lilly, Jenapharm, AMS, Janssen, Pfizer, Takeda, MSD, Gr\u00fcnenthal, AAA\/Novartis; Besitz von Gesch\u00e4ftsanteilen, Aktien, Fonds mit Beteiligung von Unternehmen der Gesundheitswissenschaft; Bristol-Myers Squibb. M.\u00a0Fr\u00f6hner gibt an, dass kein Interessenkonflikt besteht. C.\u00a0Fiebig: Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Merck Healthcare Germany GmbH; Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Deutsche Forschungsgemeinschaft (DFG). A.\u00a0Piotrowski: Mitarbeit in einem wissenschaftlichen Beirat (advisory board): Firma Bayer; Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Firma Pfleger. M.\u00a0Schl\u00f6gl: Berater- bzw. Gutachtert\u00e4tigkeiten: Dr\u00e4ger AG; Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Abbot, Lundbeck; Indirekte Interessen \u2013\u00a0Mitgliedschaften: Schweizerische Gesellschaft f\u00fcr Geriatrie, Deutsche Gesellschaft f\u00fcr Geriatrie. A.\u00a0Wiedemann: Berater- bzw. Gutachtert\u00e4tigkeiten: Acticore, Astellas, Bayer Pharma, Dr.\u00a0Pfleger, Merck, MIP Arzneimittel, Novartis; Mitarbeit in einem wissenschaftlichen Beirat (advisory board): Dr.\u00a0Pfleger, Pfizer, MIP Arzneimittel, Bayer, Novartis; Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Allergan, AMS Deutschland, Aristo, Astellas Pharma, Bayer Pharma, Besins Deutschland, Berlin-Chemie, Das Fortbildungskolleg, Jansen, Lilly Deutschland, Meda, Merck, MIP Arzneimittel, Novartis, Dr. Pfleger, Pierre Fabre, Pfizer Pharma; Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: AMS Deutschland, Boston Scientific, Dr.\u00a0Pfleger, Paul-Kuth-Stiftung der Deutschen Bank; Indirekte Interessen\u00a0\u2013 Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie (aktuell Leitung Arbeitskreis geriatrische Urologie), Deutsche Gesellschaft f\u00fcr Geriatrie (aktuell Leitung Arbeitsgruppe Harinkontinenz), NRW-Gesellschaft f\u00fcr Urologie (gew\u00e4hlt zum Kongresspr\u00e4sidenten 2025), Deutsche Kontinenzgesellschaft (aktuell 1.\u00a0Vorsitzender), Institut f\u00fcr Geriatrische Pharmazie und interdisziplin\u00e4re Geriatrie e.\u202fV.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}